Edwin Lee, MD
Interventional Cardiology · Los Angeles, CANPI 1629244918
Payments from drug & device makers
Across 552 payments — averaging $49.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$11K
- Abbott$6K
- Bayer$1K
- Novartis$1K
- AstraZeneca$982
- Actelion Pharmaceuticals US, Inc.$791
- plus $6K from 27 others
What the payments were for
- Speaking & faculty fees$8,25030%
- Food & beverage$18,51368%
- Education$3941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 100 | $10,886 |
| Abbott | 79 | $6,217 |
| Bayer | 50 | $1,443 |
| Novartis | 56 | $1,117 |
| AstraZeneca | 46 | $982 |
| Actelion Pharmaceuticals US, Inc. | 42 | $791 |
| Medtronic | 8 | $695 |
| Amgen | 28 | $596 |
| Merck | 23 | $570 |
| Boehringer Ingelheim | 17 | $497 |
| Shockwave Medical, Inc | 4 | $467 |
| Pfizer | 19 | $433 |
| Astellas Pharma US Inc | 11 | $343 |
| Lexicon Pharmaceuticals, Inc. | 8 | $216 |
| Kestra Medical Technology Services, Inc. | 2 | $199 |
| Acist Medical Systems, Inc. | 9 | $196 |
| Kiniksa Pharmaceuticals International, PLC | 9 | $191 |
| Johnson & Johnson(2 entities) | 8 | $187 |
| Novo Nordisk | 8 | $182 |
| Penumbra, Inc. | 1 | $149 |
| Heartflow, Inc. | 4 | $141 |
| Bardy Diagnostics, Inc. | 3 | $137 |
| Impulse Dynamics (USA) Inc. | 3 | $131 |
| Lilly USA, LLC | 3 | $87 |
| Scpharmaceuticals Inc. | 2 | $59 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $46 |
| Cathworks, Inc. | 1 | $42 |
| Abiomed | 1 | $38 |
| Teleflex LLC | 1 | $36 |
| Boston Scientific | 1 | $25 |
| Terumo Medical Corporation | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$8,372
- Confirm Rx$1,039
- Fortify Assura, Ellipse ICD$649
- Merlin Connectivity and Remote$510
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$458
- Dragonfly OCT$327
- Optisure Defibrillation ICD Lead$269
- Quadra Assura CRT Defibrillator$237
- PRESSUREWIRE$189
- LINQ II$173
- MERLIN@HOME$149
- Quadra Allure MP RF CRT Pacemkr$149
- Indigo System$149
- Resolute$139
- Xience Sierra Coronary Stent System$128
- AURORA EV-ICD MRI SURESCAN$122
- ADVISA DR MRI SURESCAN$117
- AVEIR$115
- AGILIS$115
- Nanostim Leadleas Pacemaker$108
How this compares
$27,158 in reported general payments places this provider in the 70th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 36 | $435,741 |
| EntrestoSacubitril/Valsartan | 229 | $239,053 |
| EliquisApixaban | 129 | $131,974 |
| Repatha SureclickEvolocumab | 104 | $72,440 |
| KerendiaFinerenone | 49 | $63,466 |
| JardianceEmpagliflozin | 52 | $57,602 |
| FarxigaDapagliflozin Propanediol | 51 | $44,889 |
| VerquvoVericiguat | 27 | $28,541 |
| OzempicSemaglutide | 18 | $25,160 |
| BrilintaTicagrelor | 27 | $23,053 |
| TrulicityDulaglutide | 18 | $19,201 |
| Praluent PenAlirocumab | 19 | $9,336 |
| InpefaSotagliflozin | 11 | $6,270 |
| Amiodarone Hcl | 34 | $2,903 |
| Digoxin | 24 | $2,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $791 | $435,74136 claims |
| NovartisEntresto | $1,117 | $239,053229 claims |
| PfizerEliquis | $433 | $131,974129 claims |
| AstraZenecaFarxiga, Brilinta | $982 | $67,94178 claims |
| BayerKerendia | $1,443 | $63,46649 claims |
| Boehringer IngelheimJardiance | $497 | $57,60252 claims |
| MerckVerquvo | $570 | $28,54127 claims |
| Novo NordiskOzempic | $182 | $25,16018 claims |
| Lilly USA, LLCTrulicity | $87 | $19,20118 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $216 | $6,27011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Los Angeles
- Evan ZahnLos Angeles$1.4M
- Ray MatthewsLos Angeles$653K
- Steven BursteinLos Angeles$514K
- Jubin JosephLos Angeles$312K
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.